

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/119206 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/437 (2006.01)
C07D 487/04 (2006.01) A61P 3/10 (2006.01)
C07D 519/00 (2006.01) A61P 1/16 (2006.01)

(21) International Application Number:

PCT/CN2024/136693

(22) International Filing Date:

04 December 2024 (04.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/136412

05 December 2023 (05.12.2023) CN

PCT/CN2024/105568

15 July 2024 (15.07.2024) CN

(71) Applicant: **FORTVITA BIOLOGICS INC.** [GB/GB];
Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavil-
ion, Hibiscus Way, 802 West Bay Road, Grand Cayman
KY1-1205 (KY).

(72) Inventors: **XU, Lianhong**; 168 Dongping Street, Suzhou
Industrial Park, Suzhou, Jiangsu 215123 (CN). **YU, Nan**;
168 Dongping Street, Suzhou Industrial Park, Suzhou,
Jiangsu 215123 (CN). **REN, Decheng**; 168 Dongping
Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123
(CN). **XIONG, Yao**; 168 Dongping Street, Suzhou Indus-
trial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: **ZHONGZI LAW OFFICE**; 7F, New Era Building,
26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,


RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: GLP-1 RECEPTOR TARGETING COMPOUNDS AND USES THEREOF



(I)

(57) Abstract: The present disclosure relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof, stereoisomer thereof, analog thereof, solvate thereof, prodrug thereof, and/or tautomer thereof, as well as pharmaceutical compositions including such a compound, wherein the variables are as defined in the specification. Also described are method of using such compounds and pharmaceutical compositions to treat GLP-1 associated diseases, disorders, or conditions.



WO 2025/119206 A1